William P Werschler, Jeffrey Sugarman, Neal Bhatia, Hilary Baldwin, Lawrence J Green, Ori Nov, Vered Ram, Ofra Levy-Hacham, Linda Stein Gold
OBJECTIVE: We sought to assess the long-term safety and tolerability of microencapsulated benzoyl peroxide cream, 5% (E-BPO cream, 5%), in subjects with rosacea. Efficacy and tolerability have been previously demonstrated in two 12-week, randomized, double-blind, vehicle-controlled Phase III trials. METHODS: In this open-label extension study (NCT03564145; clinicaltrials.gov), all subjects from the initial placebo-controlled Phase III trials could receive E-BPO cream, 5%, for up to an additional 40 weeks, up to a total of 52 weeks of E-BPO cream, 5%, exposure...
August 2023: Journal of Clinical and Aesthetic Dermatology